Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Indole derivatives

a technology of indole and derivatives, applied in the field of indole derivatives, can solve the problems of significant hypoglycemia, edema and heart failure, anti-diabetic agents have various side effects, etc., and achieve favorable characteristics in side effects and/or commercial viability, excellent blood glucose lowering effect, and the effect of excellent

Inactive Publication Date: 2010-12-14
MITSUBISHI TANABE PHARMA CORP
View PDF58 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024]The compounds of the present invention possess activity as inhibitors of sodium-dependent glucose transporters, and show excellent blood glucose lowering effect.

Problems solved by technology

However, these anti-diabetic agents have various side effects.
For example, biguanides cause lactic acidosis, sulfonylureas cause significant hypoglycemia, insulin-sensitizing agents cause edema and heart failure, and α-glucosidase inhibitors cause abdominal bloating and diarrhea.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Indole derivatives
  • Indole derivatives
  • Indole derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

3-(4-Cyclopropylphenylmethyl)-4-fluoro-1-(β-D-gluco-pyranosyl)indole

[0106]

(1) A mixture of 4-fluoroindoline (185 mg) and D-glucose (267 mg) in H2O (0.74 ml)-ethyl alcohol (9 ml) was refluxed under argon atmosphere for 24 hours. The solvent was evaporated under reduced pressure to give crude 4-fluoro-1-(β-D-glucopyranosyl)indoline, which was used in the subsequent step without further purification.

(2) The above compound was suspended in chloroform (8 ml), and thereto were added successively pyridine (0.873 ml), acetic anhydride (1.02 ml) and 4-(dimethylamino)pyridine (a catalytic amount). After being stirred at room temperature for 21 hours, the reaction solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, and the solution was washed with a 10% aqueous copper (II) sulfate solution twice and a saturated aqueous sodium hydrogen carbonate solution, and dried over magnesium sulfate. The insoluble materials were filtered off, and the filtrate was evap...

example 2

4-Chloro-3-(4-cyclopropylphenyl-methyl)-1-(β-D-glucopyranosyl)indole

[0107]

(1) A mixture of 4-chloroindoline (2.88 g) and D-glucose (3.38 g) in ethyl alcohol (150 ml)-H2O (10 ml) was refluxed under argon atmosphere overnight. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0-88:12) to give 4-chloro-1-(β-D-glucopyranosyl)indoline (3.35 g) as a colorless foam. APCI-Mass m / Z 316 / 318 (M+H). 1H-NMR (DMSO-d6) δ 2.87-3.02 (m, 2H), 3.07-3.12 (m, 1H), 3.20-3.32 (m, 2H), 3.38-3.47 (m, 2H), 3.51-3.60 (m, 2H), 3.68-3.73 (m, 1H), 4.34-4.37 (m, 1H), 4.63 (d, J=8.3-Hz, 1H), 4.93 (d, J=5.1 Hz, 1H), 5.03 (d, J=4.0 Hz, 1H), 5.06 (d, J=4.5 Hz, 1H), 6.53 (d, J=8.0 Hz, 1H), 6.60 (d, J=8.0 Hz, 1H), 6.99 (t, J=7.9 Hz, 1H).

(2) The above compound (3.3 g) was dissolved in 1,4-dioxane (150 ml), and thereto was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (2.85 g). The mixture was stirred at room temperature for 12 ho...

example 3

3-(4-Cyclopropylphenylmethyl)-4,6-difluoro-1-(β-D-gluco-pyranosyl) indole

[0108]

[0109]The titled compound was obtained as colorless foam in a manner similar to Example 1 from 4,6-difluoroindoline. APCI-Mass m / Z 463 (M+NH4). 1H-NMR (DMSO-d6) δ 0.58-0.62 (m, 2H), 0.88-0.91 (m, 2H), 1.82-1.88 (m, 1H), 3.20-3.50 (m, 4H), 3.59-3.70 (m, 2H), 3.99 (s, 2H), 4.54 (t, J=5.7 Hz, 1H), 5.10 (d, J=5.3 Hz, 1H), 5.19 (d, J=5.0 Hz, 1H), 5.22 (d, J=5.8 Hz, 1H), 5.35 (d, J=9.0 Hz, 1H), 6.78 (t, J=9.6 Hz, 1H), 6.96 (d, J=8.0 Hz, 2H), 7.11 (d, J=8.0 Hz, 2H), 7.22 (s, 1H), 7.30 (dd, J=10.0, 1.7 Hz, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1 is fluorine, or chlorine, and R2 is hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.

Description

[0001]This Nonprovisional application claims priority under 35 U.S.C. §119(e) on U.S. Provisional Application No(s). 60 / 820,604 and 60 / 886,178 filed on Jul. 27, 2006 and Jan. 23, 2007; respectively, the entire contents of which are hereby incorporated by reference.TECHNICAL FIELD[0002]The present invention relates to novel indole derivatives possessing activity as inhibitors of sodium-dependent glucose transporters (SGLT) found in the intestine or kidney.BACKGROUND ART[0003]Diet therapy and exercise therapy are essential in the treatment of diabetes mellitus. When these therapies do not sufficiently control conditions of patients, insulin or anti-diabetic agents are used. Examples of the anti-diabetic agents include, at the present, biguanides, sulfonylureas, insulin-sensitizing agents and α-glucosidase inhibitors. However, these anti-diabetic agents have various side effects. For example, biguanides cause lactic acidosis, sulfonylureas cause significant hypoglycemia, insulin-sensit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07H19/044C07H19/056A61K31/70A01N43/04
CPCC07H19/04A61P13/12A61P17/02A61P25/00A61P25/18A61P3/00A61P3/04A61P3/06A61P3/08A61P7/00A61P9/10A61P9/12A61P3/10C07D405/06C07D405/04A61K31/706
Inventor NOMURA, SUMIHIROSAKAMAKI, SHIGEKI
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com